BR112016023688A2 - célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada - Google Patents
célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isoladaInfo
- Publication number
- BR112016023688A2 BR112016023688A2 BR112016023688A BR112016023688A BR112016023688A2 BR 112016023688 A2 BR112016023688 A2 BR 112016023688A2 BR 112016023688 A BR112016023688 A BR 112016023688A BR 112016023688 A BR112016023688 A BR 112016023688A BR 112016023688 A2 BR112016023688 A2 BR 112016023688A2
- Authority
- BR
- Brazil
- Prior art keywords
- bioconjugate
- individual
- composition
- pseudomonas
- host cell
- Prior art date
Links
- 241000589516 Pseudomonas Species 0.000 title abstract 2
- 208000032536 Pseudomonas Infections Diseases 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical group 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
são descritas aqui células hospedeiras modificadas úteis na produção de bioconjugados que podem ser usados para vacinar indivíduos contra infecção por pseudomonas. os genomas das células hospedeiras modificadas aqui descritas compreendem genes que codificam proteínas envolvidas na glicosilação de proteínas, assim como genes específicos para a produção de antígenos específicos de pseudomonas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461980988P | 2014-04-17 | 2014-04-17 | |
US61/980988 | 2014-04-17 | ||
PCT/EP2014/071898 WO2015158403A1 (en) | 2014-04-17 | 2014-10-13 | Modified host cells and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016023688A2 true BR112016023688A2 (pt) | 2018-01-30 |
BR112016023688B1 BR112016023688B1 (pt) | 2024-01-09 |
Family
ID=51726491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016023688-2A BR112016023688B1 (pt) | 2014-04-17 | 2014-10-13 | Bioconjugado e uso de um bioconjugado |
Country Status (17)
Country | Link |
---|---|
US (1) | US20170035900A1 (pt) |
EP (2) | EP3131577B1 (pt) |
JP (2) | JP6682451B2 (pt) |
CN (1) | CN106794237B (pt) |
BR (1) | BR112016023688B1 (pt) |
CA (1) | CA2945542C (pt) |
CY (1) | CY1123403T1 (pt) |
DK (1) | DK3131577T3 (pt) |
ES (2) | ES2939470T3 (pt) |
HR (1) | HRP20201021T1 (pt) |
HU (1) | HUE049806T2 (pt) |
LT (1) | LT3131577T (pt) |
MX (1) | MX2016013631A (pt) |
PL (1) | PL3131577T3 (pt) |
PT (1) | PT3131577T (pt) |
SI (1) | SI3131577T1 (pt) |
WO (1) | WO2015158403A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
CN105732818B (zh) * | 2016-03-02 | 2019-06-07 | 中国人民解放军第三军医大学 | 一种铜绿假单胞菌重组蛋白pop及其制备方法和应用 |
KR20200041311A (ko) | 2017-06-23 | 2020-04-21 | 노소코미얼 백신 코포레이션 | 면역원성 조성물 |
US11993778B2 (en) | 2017-10-25 | 2024-05-28 | Pivot Bio, Inc. | Methods and compositions for improving engineered microbes that fix nitrogen |
BR112020026676A2 (pt) * | 2018-06-27 | 2021-08-03 | Pivot Bio, Inc. | remodelação microbiana guiada, uma plataforma para a melhoria racional de espécies microbianas para agricultura |
WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
AR118389A1 (es) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
CN115698273A (zh) * | 2020-03-12 | 2023-02-03 | 马尔西博股份有限公司 | 包含糖工程化细菌的疫苗 |
IL301248B2 (en) | 2020-09-17 | 2024-04-01 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and their uses |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US20050287628A1 (en) | 2002-03-07 | 2005-12-29 | Markus Aebi | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
AU2006245969B8 (en) | 2005-05-11 | 2011-08-25 | Eth Zurich | Recombinant N-glycosylated proteins from procaryotic cells |
US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
US8895014B2 (en) * | 2008-02-20 | 2014-11-25 | Glycovaxyn Ag | Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells |
AU2010322454B2 (en) * | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
CN103079591B (zh) * | 2010-05-06 | 2017-07-28 | 格林考瓦因有限公司 | 荚膜革兰氏阳性细菌生物缀合物疫苗 |
AU2012306345A1 (en) * | 2011-09-06 | 2014-03-20 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
AU2013311534A1 (en) * | 2012-09-10 | 2015-03-12 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
EA201590488A1 (ru) * | 2012-10-12 | 2015-09-30 | Гликоваксин Аг | Способы модификации клеток-хозяев |
CN105008539B (zh) * | 2012-11-07 | 2020-04-17 | 葛兰素史密丝克莱恩生物有限公司 | 通过酶缀合在大肠杆菌中生产重组疫苗 |
ES2778074T3 (es) * | 2013-10-11 | 2020-08-07 | Glaxosmithkline Biologicals Sa | Procedimientos de modificación de células hospedadoras |
-
2014
- 2014-10-13 MX MX2016013631A patent/MX2016013631A/es unknown
- 2014-10-13 EP EP14784210.8A patent/EP3131577B1/en active Active
- 2014-10-13 ES ES20170090T patent/ES2939470T3/es active Active
- 2014-10-13 DK DK14784210.8T patent/DK3131577T3/da active
- 2014-10-13 US US15/304,557 patent/US20170035900A1/en not_active Abandoned
- 2014-10-13 CA CA2945542A patent/CA2945542C/en active Active
- 2014-10-13 CN CN201480079804.3A patent/CN106794237B/zh active Active
- 2014-10-13 BR BR112016023688-2A patent/BR112016023688B1/pt active IP Right Grant
- 2014-10-13 WO PCT/EP2014/071898 patent/WO2015158403A1/en active Application Filing
- 2014-10-13 LT LTEP14784210.8T patent/LT3131577T/lt unknown
- 2014-10-13 HU HUE14784210A patent/HUE049806T2/hu unknown
- 2014-10-13 SI SI201431611T patent/SI3131577T1/sl unknown
- 2014-10-13 PT PT147842108T patent/PT3131577T/pt unknown
- 2014-10-13 ES ES14784210T patent/ES2805000T3/es active Active
- 2014-10-13 JP JP2016562754A patent/JP6682451B2/ja active Active
- 2014-10-13 EP EP20170090.3A patent/EP3711776B1/en active Active
- 2014-10-13 PL PL14784210T patent/PL3131577T3/pl unknown
-
2020
- 2020-03-25 JP JP2020053544A patent/JP2020114232A/ja active Pending
- 2020-06-29 HR HRP20201021TT patent/HRP20201021T1/hr unknown
- 2020-07-09 CY CY20201100633T patent/CY1123403T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HUE049806T2 (hu) | 2020-10-28 |
EP3711776B1 (en) | 2023-01-11 |
CN106794237A (zh) | 2017-05-31 |
DK3131577T3 (da) | 2020-07-13 |
EP3131577A1 (en) | 2017-02-22 |
CY1123403T1 (el) | 2022-03-24 |
PL3131577T3 (pl) | 2020-10-19 |
JP2020114232A (ja) | 2020-07-30 |
BR112016023688B1 (pt) | 2024-01-09 |
EP3711776A1 (en) | 2020-09-23 |
CN106794237B (zh) | 2022-04-12 |
JP6682451B2 (ja) | 2020-04-15 |
PT3131577T (pt) | 2020-07-17 |
HRP20201021T1 (hr) | 2020-10-16 |
ES2805000T3 (es) | 2021-02-10 |
SI3131577T1 (sl) | 2020-08-31 |
WO2015158403A1 (en) | 2015-10-22 |
US20170035900A1 (en) | 2017-02-09 |
MX2016013631A (es) | 2017-02-28 |
LT3131577T (lt) | 2020-07-27 |
CA2945542A1 (en) | 2015-10-22 |
JP2017513480A (ja) | 2017-06-01 |
CA2945542C (en) | 2024-03-05 |
ES2939470T3 (es) | 2023-04-24 |
EP3131577B1 (en) | 2020-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016023688A2 (pt) | célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada | |
BR112017019140A2 (pt) | métodos de tratamento de câncer usando células t ativadas | |
MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
CY1122800T1 (el) | Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων | |
BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
CL2021000636A1 (es) | Vacuna contra el virus de la peste porcina africana | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
BR112019006384A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
BR112017006203A2 (pt) | anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune. | |
BR112018072485A2 (pt) | proteínas de ligação biespecíficas e usos das mesmas | |
BR112017023975A2 (pt) | variantes de alfa-amilase e polinucleotídeos codificando as mesmas | |
MX2018003037A (es) | Produccion de oligosacaridos de leche humana en huespedes microbianos con importacion/exportacion diseñada. | |
WO2018132739A3 (en) | T cell receptors that bind to ny-eso-1 and methods of use thereof | |
BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
BR112019000621A2 (pt) | anticorpos tgfss, métodos e usos | |
BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
BR112016007727A2 (pt) | célula hospedeira, métodos para produzir um glicoconjugado, uma célula hospedeira e uma proteína n-glicosilada, para tratar ou prevenir uma infecção em um indivíduo e para induzir uma resposta imune em um indivíduo, glicoconjugado, kit, e, plasmídeo isolado | |
CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
BR112018012694A2 (pt) | composição de célula dendrítica, vacina de célula dendrítica, composição e kit | |
CO2018012513A2 (es) | Anticuerpos | |
BR112017023131A2 (pt) | anticorpos anti- fcrn | |
BR112018010937A2 (pt) | composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação | |
MX2020003504A (es) | Receptores de celulas t que reconocen p53 mutado. | |
BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA (BE) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2014, OBSERVADAS AS CONDICOES LEGAIS |